PureTech Health PLC Cash Flow Conversion Efficiency
PureTech Health PLC cash flow conversion efficiency. Based on the latest financial reports, PureTech Health PLC (PRTC) has a cash flow conversion efficiency ratio of -0.126x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-38.47 Million) by net assets ($305.68 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of PureTech Health PLC (2012–2025)
Cash flow conversion efficiency of PureTech Health PLC from 2012 to 2025. This chart illustrates how PureTech Health PLC's cash flow conversion efficiency has evolved over time, based on yearly financial data. View PureTech Health PLC stock price for real-time trading data and today's change.
PureTech Health PLC Cash Flow Conversion Ratio Explained
PureTech Health PLC cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
PureTech Health PLC Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of PureTech Health PLC ranked by their cash flow conversion efficiency. Also see PRTC market cap overview for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
ValueHD Corp. A
SHE:301318
|
0.002x |
|
Pes Camanchaca
SN:CAMANCHACA
|
0.052x |
|
InBody Co.Ltd
KQ:041830
|
0.032x |
|
EUROKAI GmbH & Co. KGaA
F:EUK3
|
0.017x |
|
Lifecome Biochemistry Co Ltd
SHE:002868
|
-1.556x |
|
L&C Bio Co. Ltd
KQ:290650
|
0.014x |
|
Objective Corporation Ltd
AU:OCL
|
0.194x |
|
CorMedix Inc
NASDAQ:CRMD
|
0.233x |
Annual Cash Flow Conversion Efficiency for PureTech Health PLC (2012–2025)
The table below shows the annual cash flow conversion efficiency of PureTech Health PLC from 2012 to 2025. Review PureTech Health PLC (PRTC) financial flexibility to assess the company's free cash flow relative to its total liabilities.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $305.68 Million | $-85.33 Million | -0.279x | +15.25% |
| 2024-12-31 | $407.93 Million | $-134.37 Million | -0.329x | -42.50% |
| 2023-12-31 | $458.23 Million | $-105.92 Million | -0.231x | +29.21% |
| 2022-12-31 | $547.59 Million | $-178.79 Million | -0.327x | -20.51% |
| 2021-12-31 | $584.15 Million | $-158.27 Million | -0.271x | -34.32% |
| 2020-12-31 | $653.54 Million | $-131.83 Million | -0.202x | -33.66% |
| 2019-12-31 | $650.40 Million | $-98.16 Million | -0.151x | +65.38% |
| 2018-12-31 | $166.97 Million | $-72.80 Million | -0.436x | +68.54% |
| 2017-12-31 | $64.00 Million | $-88.69 Million | -1.386x | -120.68% |
| 2016-12-31 | $92.41 Million | $-58.03 Million | -0.628x | -260.08% |
| 2015-12-31 | $164.05 Million | $-28.61 Million | -0.174x | -121.14% |
| 2014-12-31 | $133.69 Million | $-10.54 Million | -0.079x | -107.21% |
| 2013-12-31 | $-8.03 Million | $-8.77 Million | 1.093x | +152.49% |
| 2012-12-31 | $-3.35 Million | $-1.45 Million | 0.433x | -- |
About PureTech Health PLC
PureTech Health plc, engages in the development and commercialization of biotechnology and pharmaceutical solutions in the United States. It is developing LYT-100, which is under Phase 2 stage, to treat idiopathic pulmonary fibrosis (IPF); and LYT-200, a IgG4 monoclonal antibody, currently under Phase 1/2 stage, targeting galectin-9 for treating solid tumors and hematological malignancies. The co… Read more